Cargando…
Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts
SIMPLE SUMMARY: Mucinous adenocarcinoma develops in 10–20% of all colorectal cancer (CRC) cases. This subtype is characterized by its worse clinicopathological features, including but not limited to more advanced stages at the time of tumor diagnosis, it being more frequent in the proximal colon, it...
Autores principales: | Herold, Zoltan, Acs, Miklos, Szasz, Attila Marcell, Olasz, Katalin, Hussong, Jana, Mayr, Max, Dank, Magdolna, Piso, Pompiliu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406628/ https://www.ncbi.nlm.nih.gov/pubmed/36010972 http://dx.doi.org/10.3390/cancers14163978 |
Ejemplares similares
-
Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
por: Acs, Miklos, et al.
Publicado: (2022) -
Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Kartik, Akash, et al.
Publicado: (2023) -
Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases
por: Steinhoff, Heinrich, et al.
Publicado: (2023) -
The use of Hypotension Prediction Index in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Gangakhedkar, Gauri R., et al.
Publicado: (2022) -
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis
por: Vassos, Nikolaos, et al.
Publicado: (2016)